MX2015015200A - Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. - Google Patents
Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos.Info
- Publication number
- MX2015015200A MX2015015200A MX2015015200A MX2015015200A MX2015015200A MX 2015015200 A MX2015015200 A MX 2015015200A MX 2015015200 A MX2015015200 A MX 2015015200A MX 2015015200 A MX2015015200 A MX 2015015200A MX 2015015200 A MX2015015200 A MX 2015015200A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- compositions
- products
- nicotinamide phosphoribosyltransferase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Los compuestos de la fórmula (I): (ver Fórmula) son capaces de inhibir nicotamida fosforibosiltransferasa. La divulgación también se refiere al uso de los compuestos de la fórmula (I) para tratamiento de condiciones patológicas en donde la inhibición de NAMPT podría ser beneficiosa, tal como en inflamación aguda y crónica, cáncer y desórdenes metabólicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000356A ITTO20130356A1 (it) | 2013-05-03 | 2013-05-03 | Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi |
PCT/IB2014/061080 WO2014178001A1 (en) | 2013-05-03 | 2014-04-29 | "inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof" |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015200A true MX2015015200A (es) | 2016-06-06 |
Family
ID=48748449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015200A MX2015015200A (es) | 2013-05-03 | 2014-04-29 | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160075682A1 (es) |
EP (1) | EP2991975B1 (es) |
JP (1) | JP2016517879A (es) |
KR (1) | KR20160003196A (es) |
CN (1) | CN105531269A (es) |
AR (1) | AR096160A1 (es) |
AU (1) | AU2014261094A1 (es) |
BR (1) | BR112015027629A2 (es) |
CA (1) | CA2910255A1 (es) |
EA (1) | EA028303B1 (es) |
IT (1) | ITTO20130356A1 (es) |
MX (1) | MX2015015200A (es) |
SG (1) | SG11201508677QA (es) |
WO (1) | WO2014178001A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153020A (zh) * | 2015-07-20 | 2015-12-16 | 湖南华腾制药有限公司 | 一种芳香叠氮化合物的制备方法 |
KR20190092374A (ko) * | 2016-10-03 | 2019-08-07 | 시질론 테라퓨틱스, 인크. | 화합물, 장치, 및 이의 용도 |
MA46660A (fr) | 2016-10-18 | 2019-08-28 | Seattle Genetics Inc | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide |
CN110799217A (zh) | 2017-04-27 | 2020-02-14 | 西雅图基因公司 | 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物 |
AU2019371161A1 (en) * | 2018-10-31 | 2021-06-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers and methods of use for radiation-induced lung injury |
-
2013
- 2013-05-03 IT IT000356A patent/ITTO20130356A1/it unknown
-
2014
- 2014-04-29 AU AU2014261094A patent/AU2014261094A1/en not_active Abandoned
- 2014-04-29 MX MX2015015200A patent/MX2015015200A/es unknown
- 2014-04-29 EP EP14728327.9A patent/EP2991975B1/en not_active Not-in-force
- 2014-04-29 SG SG11201508677QA patent/SG11201508677QA/en unknown
- 2014-04-29 JP JP2016511155A patent/JP2016517879A/ja active Pending
- 2014-04-29 EA EA201592096A patent/EA028303B1/ru not_active IP Right Cessation
- 2014-04-29 WO PCT/IB2014/061080 patent/WO2014178001A1/en active Application Filing
- 2014-04-29 KR KR1020157034043A patent/KR20160003196A/ko not_active Application Discontinuation
- 2014-04-29 CA CA2910255A patent/CA2910255A1/en not_active Abandoned
- 2014-04-29 BR BR112015027629A patent/BR112015027629A2/pt not_active Application Discontinuation
- 2014-04-29 CN CN201480034005.4A patent/CN105531269A/zh active Pending
- 2014-04-29 US US14/888,597 patent/US20160075682A1/en not_active Abandoned
- 2014-04-30 AR ARP140101791A patent/AR096160A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2991975B1 (en) | 2017-07-19 |
WO2014178001A1 (en) | 2014-11-06 |
EP2991975A1 (en) | 2016-03-09 |
CN105531269A (zh) | 2016-04-27 |
ITTO20130356A1 (it) | 2014-11-04 |
KR20160003196A (ko) | 2016-01-08 |
AR096160A1 (es) | 2015-12-09 |
AU2014261094A1 (en) | 2015-11-12 |
EA201592096A1 (ru) | 2016-03-31 |
BR112015027629A2 (pt) | 2017-08-22 |
US20160075682A1 (en) | 2016-03-17 |
EA028303B1 (ru) | 2017-10-31 |
CA2910255A1 (en) | 2014-11-06 |
SG11201508677QA (en) | 2015-11-27 |
JP2016517879A (ja) | 2016-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
WO2014028597A3 (en) | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
NZ700928A (en) | Dna-pk inhibitors | |
MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
MX2016003861A (es) | Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
MX2016001136A (es) | Derivados de oxoquinazolinil-butanamida. | |
MX2018001756A (es) | Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos. | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
MX2015015200A (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. | |
WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists | |
MX364859B (es) | Derivados de imidazopirazinona. | |
MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
MX2016001536A (es) | Derivados de urea de piperidinas. | |
MX2015008912A (es) | Carboxamidas basadas en pirazolilo ii como inhibidores del canal de calcio activado por liberacion de calcio (crac). | |
MX2015008919A (es) | Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac). | |
MX2015016760A (es) | Derivados de ftalazina. |